LM Advisors’s Editas Medicine EDIT Stock Holding History

LM Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-50	Closed	-$507	–	351
2023 Q4	$507	Buy	+50	New	+$439	﹤0.01%	715

Other funds holding EDIT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

LM Advisors's EDIT Position: Q1 2024 in Review

LM Advisors sold out of Editas Medicine (EDIT) in Q1 2024, closing a stake of 50 shares — an estimated $507 sold.

LM Advisors first reported a position in EDIT in Q4 2023 and held it in 1 quarter. The position peaked at $507 in Q4 2023. 225 funds tracked by Wall St. Rank hold EDIT as of Q1 2024.

LM Advisors reported no remaining Editas Medicine position as of Q1 2024 after selling out during the quarter.
LM Advisors sold 50 Editas Medicine shares in Q1 2024, an estimated $507.
LM Advisors first reported a position in Editas Medicine in Q4 2023 and held it in 1 quarter.
LM Advisors's Editas Medicine position peaked at $507 in Q4 2023.
225 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2024.

Based on LM Advisors's 13F filing for Q1 2024, filed 15 May 2024.